For research use only. Not for therapeutic Use.
Cinromide (Cat No.: I020436) is an anticonvulsant drug known for its inhibition of the epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 of 0.5 μM. This inhibition affects the absorption of neutral amino acids in the small intestine, potentially impacting amino acid balance in the body. If you require further information or have inquiries, please don’t hesitate to contact us, and we will respond promptly within 24 hours.
| Catalog Number | I020436 |
| CAS Number | 58473-74-8 |
| Molecular Formula | C₁₁H₁₂BrNO |
| Purity | ≥95% |
| Storage | Room Temperature |
| IUPAC Name | (E)-3-(3-bromophenyl)-N-ethylprop-2-enamide |
| InChI | InChI=1S/C11H12BrNO/c1-2-13-11(14)7-6-9-4-3-5-10(12)8-9/h3-8H,2H2,1H3,(H,13,14)/b7-6+ |
| InChIKey | LDCXGZCEMNMWIL-VOTSOKGWSA-N |
| SMILES | CCNC(=O)C=CC1=CC(=CC=C1)Br |
| Reference | [1]. Chiu P, et al. The effect of cinromide on “kindled” seizures in the rat. Neuropharmacology. 1982;21(3):273-276.<br>[2]. Yadav A, et al. Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases. Front Pharmacol. 2020;11:140. Published 2020 Feb 28.<br>[3]. Soroko FE, et al. Cinromide (3-bromo-N-ethylcinnanamide), novel anticonvulsant agent. J Pharm Pharmacol. 1981 Nov;33(11):741-3.<br>[4]. Fromm GH, et al. Effect of cinromide on inhibitory and excitatory mechanisms. Epilepsia. 1983 Aug;24(4):394-400. |
